PiperJaffray Reiterates Overweight on Adverum Biotechnologies, Raises Price Target to $20

PiperJaffray analyst Tyler Van Buren reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Overweight and raises the price target from $14 to $20.

Benzinga · 01/13/2020 12:41

PiperJaffray analyst Tyler Van Buren reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Overweight and raises the price target from $14 to $20.